Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $66.00

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $66.00.

CLDX has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Friday, March 22nd. Finally, Guggenheim lifted their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th.

Celldex Therapeutics Stock Down 0.6 %

NASDAQ:CLDX opened at $39.94 on Friday. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18. The stock’s 50-day simple moving average is $40.74 and its 200 day simple moving average is $37.60. The firm has a market capitalization of $2.63 billion, a PE ratio of -14.01 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.19. The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. On average, analysts anticipate that Celldex Therapeutics will post -2.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CLDX. Price T Rowe Associates Inc. MD increased its position in Celldex Therapeutics by 631.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after buying an additional 2,664,915 shares in the last quarter. Eventide Asset Management LLC increased its position in shares of Celldex Therapeutics by 126.9% during the fourth quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock valued at $143,966,000 after acquiring an additional 2,030,013 shares during the last quarter. Point72 Asset Management L.P. grew its stake in Celldex Therapeutics by 105.3% in the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after purchasing an additional 1,413,722 shares during the period. Wellington Management Group LLP increased its position in shares of Celldex Therapeutics by 19.2% during the 4th quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after purchasing an additional 1,044,728 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Celldex Therapeutics by 3,327.0% during the 1st quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock worth $28,879,000 after purchasing an additional 668,002 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.